A phase II basket trial of dual anti‐CTLA‐4 and anti‐PD‐1 blockade in rare tumors (DART) SWOG S1609: durable responses and delayed pseudoprogression in small cell carcinoma of the ovary, hypercalcemic type cohort
Cancer Communications · 2025
DOI: 10.1002/cac2.70020 ↗Kurz gefasst
Klinische Studie (Phase II) in der Zeitschrift Cancer Communications, 2025. Verfasst von Young Kwang Chae und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA. Hauptthemen laut MEDLINE: CTLA-4 Antigen, Ovarian Neoplasms, Programmed Cell Death 1 Receptor, Hypercalcemia. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NCI NIH HHS, Bristol Myers Squibb Company, NIH HHS.
Abstract (Originalsprache)
Background
The combined use of anti‐programmed cell death protein 1 ( PD‐1 )/anti‐cytotoxic T‐lymphocyte associated protein 4 ( CTLA‐4) checkpoint inhibitors has been effective in various cancer types. The Southwest Oncology Group (SWOG) Dual Anti‐ CTLA‐4 and Anti‐ PD‐1 Blockade in Rare Tumors (DART) S1609 study investigated ipilimumab and nivolumab in ultra‐rare cancers, including small cell carcinoma of the ovary, hypercalcemic type (SCCOHT). The purpose of the study was to evaluate the potential clinical benefit of ipilimumab and nivolumab in patients with SCCOHT.
Methods
DART was a prospective, open‐labeled, multicenter (>1,000 US sites), multi‐cohort phase II clinical trial of intravenous administration of ipilimumab (1 mg/kg, every 6 weeks) plus nivolumab (240 mg, every 2 weeks). The primary endpoint was overall response rate [ORR, confirmed complete response (CR) and partial response (PR)] per RECIST. Secondary endpoints included progression‐free survival (PFS), overall survival (OS), clinical benefit rate (CBR; overall response plus stable disease ≥6 months), and toxicity. Immune responses were also evaluated.
Results
Six patients (median age, 30.5 years; median, 2 prior therapies; no prior immunotherapy exposure) with advanced/metastatic SCCOHT were evaluable. ORR and CBR were both 16.7% (1/6) with one patient having a confirmed CR lasting 46.2+ months. However, another patient had a confirmed immune CR (iCR) with immune PFS (iPFS) of 53+ months [ORR/iORR, 33.3% (2/6)]. Notably, the latter patient had a progressing lesion at 24 weeks after initial response, but with renewed regression with ongoing therapy, suggesting delayed pseudo‐progression. At 12‐months, 3 patients remained alive. Median PFS was 1.4 months (range, 0.9 months‐not reached); median OS was 14.2 months (2 months‐not reached). No adverse events caused treatment discontinuation.
Conclusion
Two of 6 patients (33.3%) with SCCOHT achieved durable CR/iCR and long‐term survival with ipilimumab plus nivolumab. Correlative studies to determine response and resistance markers are ongoing.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medical Oncology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA.
- SWOG Statistics and Data Management Center, Seattle, Washington, USA.
- Department of Medical Oncology, University of California at San Diego Moores Cancer Center, La Jolla, California, USA.
- Department of Oncology, Oklahoma University Health Stephenson Cancer Center, Oklahoma City, Oklahoma, USA.
- Department of Medical Oncology, UC Davis Comprehensive Cancer Center/Fremont - Rideout Cancer Center, Marysville, California, USA.
- Department of Medical Oncology, Oregon Health & Science University, Portland, Oregon, USA.
ORCID-Profile: Megan Othus
Förderung
- NCI NIH HHS
- Bristol Myers Squibb Company
- NIH HHS
- National Institutes of Health
- National Cancer Institute
Zitieren
APA
Chae, Y. K., Othus, M., Patel, S. P., Aljumaily, R., Win, K. Z., Pejovic, T., Thomas, S. S., Robinson, W. R., Kim, H. S., Chung, L. I., McLeod, C. M., Chen, H. X., Sharon, E., Streicher, H., Ryan, C. W., Blanke, C. D., & Kurzrock, R. (2025). A phase II basket trial of dual anti‐CTLA‐4 and anti‐PD‐1 blockade in rare tumors (DART) SWOG S1609: durable responses and delayed pseudoprogression in small cell carcinoma of the ovary, hypercalcemic type cohort. Cancer Communications. https://doi.org/10.1002/cac2.70020
Vancouver
Chae YK, Othus M, Patel SP, Aljumaily R, Win KZ, Pejovic T, et al. A phase II basket trial of dual anti‐CTLA‐4 and anti‐PD‐1 blockade in rare tumors (DART) SWOG S1609: durable responses and delayed pseudoprogression in small cell carcinoma of the ovary, hypercalcemic type cohort. Cancer Communications. 2025. doi:10.1002/cac2.70020
BibTeX
@article{Chae2025,
author = {Chae, Young Kwang and Othus, Megan and Patel, Sandip Pravin and Aljumaily, Raid and Win, Khine Z and Pejovic, Tanya and Thomas, Sajeve S and Robinson, William R and Kim, Hye Sung and Chung, Liam Il-Young and McLeod, Christine M and Chen, Helen X and Sharon, Elad and Streicher, Howard and Ryan, Christopher W and Blanke, Charles D and Kurzrock, Razelle},
title = {A phase II basket trial of dual anti‐CTLA‐4 and anti‐PD‐1 blockade in rare tumors (DART) SWOG S1609: durable responses and delayed pseudoprogression in small cell carcinoma of the ovary, hypercalcemic type cohort},
journal = {Cancer Communications},
year = {2025},
doi = {10.1002/cac2.70020}
}
EUVIMED